145 related articles for article (PubMed ID: 9537203)
1. Prognostic value of K-ras mutations, ras oncoprotein, and c-erb B-2 oncoprotein expression in adenocarcinoma of the lung.
Nemunaitis J; Klemow S; Tong A; Courtney A; Johnston W; Mack M; Taylor W; Solano M; Stone M; Mallams J; Mues G
Am J Clin Oncol; 1998 Apr; 21(2):155-60. PubMed ID: 9537203
[TBL] [Abstract][Full Text] [Related]
2. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
[TBL] [Abstract][Full Text] [Related]
3. The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients.
Kim YC; Park KO; Kern JA; Park CS; Lim SC; Jang AS; Yang JB
Lung Cancer; 1998 Dec; 22(3):181-90. PubMed ID: 10048471
[TBL] [Abstract][Full Text] [Related]
4. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women.
Nelson HH; Christiani DC; Mark EJ; Wiencke JK; Wain JC; Kelsey KT
J Natl Cancer Inst; 1999 Dec; 91(23):2032-8. PubMed ID: 10580029
[TBL] [Abstract][Full Text] [Related]
5. Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.
Huang CL; Taki T; Adachi M; Konishi T; Higashiyama M; Kinoshita M; Hadama T; Miyake M
Int J Oncol; 1998 Mar; 12(3):553-63. PubMed ID: 9472092
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis.
Meng D; Yuan M; Li X; Chen L; Yang J; Zhao X; Ma W; Xin J
Lung Cancer; 2013 Jul; 81(1):1-10. PubMed ID: 23608713
[TBL] [Abstract][Full Text] [Related]
7. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status.
Onitsuka T; Uramoto H; Ono K; Takenoyama M; Hanagiri T; Oyama T; Izumi H; Kohno K; Yasumoto K
J Thorac Oncol; 2010 May; 5(5):591-6. PubMed ID: 20150826
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer.
Miyamoto H; Harada M; Isobe H; Akita HD; Haneda H; Yamaguchi E; Kuzumaki N; Kawakami Y
Cancer Res; 1991 Dec; 51(23 Pt 1):6346-50. PubMed ID: 1657384
[TBL] [Abstract][Full Text] [Related]
10. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.
Kern JA; Slebos RJ; Top B; Rodenhuis S; Lager D; Robinson RA; Weiner D; Schwartz DA
J Clin Invest; 1994 Feb; 93(2):516-20. PubMed ID: 7906694
[TBL] [Abstract][Full Text] [Related]
11. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.
Yanagawa N; Leduc C; Kohler D; Saieg MA; John T; Sykes J; Yoshimoto M; Pintilie M; Squire J; Shepherd FA; Tsao MS
J Thorac Oncol; 2012 Oct; 7(10):1513-21. PubMed ID: 22982652
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer.
Graziano SL; Gamble GP; Newman NB; Abbott LZ; Rooney M; Mookherjee S; Lamb ML; Kohman LJ; Poiesz BJ
J Clin Oncol; 1999 Feb; 17(2):668-75. PubMed ID: 10080613
[TBL] [Abstract][Full Text] [Related]
13. High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway.
Levallet G; Bergot E; Antoine M; Creveuil C; Santos AO; Beau-Faller M; de Fraipont F; Brambilla E; Levallet J; Morin F; Westeel V; Wislez M; Quoix E; Debieuvre D; Dubois F; Rouquette I; Pujol JL; Moro-Sibilot D; Camonis J; Zalcman G;
Mol Cancer Ther; 2012 May; 11(5):1203-13. PubMed ID: 22411898
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
[TBL] [Abstract][Full Text] [Related]
15. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.
Schiller JH; Adak S; Feins RH; Keller SM; Fry WA; Livingston RB; Hammond ME; Wolf B; Sabatini L; Jett J; Kohman L; Johnson DH
J Clin Oncol; 2001 Jan; 19(2):448-57. PubMed ID: 11208838
[TBL] [Abstract][Full Text] [Related]
16. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung.
Slebos RJ; Kibbelaar RE; Dalesio O; Kooistra A; Stam J; Meijer CJ; Wagenaar SS; Vanderschueren RG; van Zandwijk N; Mooi WJ
N Engl J Med; 1990 Aug; 323(9):561-5. PubMed ID: 2199829
[TBL] [Abstract][Full Text] [Related]
17. K-ras gene point mutation: a stable tumor marker in non-small cell lung carcinoma.
Li S; Rosell R; Urban A; Font A; Ariza A; Armengol P; Abad A; Navas JJ; Monzo M
Lung Cancer; 1994 Jul; 11(1-2):19-27. PubMed ID: 8081702
[TBL] [Abstract][Full Text] [Related]
18. Expression of TLR9 in tumor-infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer.
Belmont L; Rabbe N; Antoine M; Cathelin D; Guignabert C; Kurie J; Cadranel J; Wislez M
Int J Cancer; 2014 Feb; 134(4):765-77. PubMed ID: 23913633
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients.
Al-Saad S; Al-Shibli K; Donnem T; Andersen S; Bremnes RM; Busund LT
J Thorac Oncol; 2010 Oct; 5(10):1536-43. PubMed ID: 20802349
[TBL] [Abstract][Full Text] [Related]
20. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
Kawesha A; Ghaneh P; Andrén-Sandberg A; Ograed D; Skar R; Dawiskiba S; Evans JD; Campbell F; Lemoine N; Neoptolemos JP
Int J Cancer; 2000 Nov; 89(6):469-74. PubMed ID: 11102889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
